Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Management appointments at Seattle Genetics

This article was originally published in Scrip

Executive Summary

Seattle Genetics has appointed Natasha Hernday vice-president of corporate development. Ms Hernday, who has 10 years' experience in business and corporate development, joins from Amgen, where she held roles of increasing responsibility in research, research project management and business development finance, before joining the corporate development group in 2000. Seattle has also promoted Dr Eric Sievers to vice-president of clinical affairs. He joined the company in 2006, most recently serving as executive medical director, and has played a leadership role in the company's brentuximab vedotin (SGN-35) programme, including the recent BLA submission to the US FDA.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts